FDA Calendar for XenoPort, Inc. (XNPT)

| Register (free)
XenoPort, Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The Company focuses on development and commercialization efforts on potential treatments of central nervous system (CNS), disorders. Its product candidate, XP13512, known in the United States by the trade name Solzira (gabapentin enacarbil) Extended Release Tablets, is being developed for the treatment of a number of CNS disorders. During the year ended December 31, 2008, XP13512 completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
GSK1838262/XP13512 Other Pending DecisionPhase 3


Events

No future events listed at this time, please check back later.
1 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

XNPT

$4.71
0.28 +6.32%
2/3/2012 4:00:00 PM

Sponsors

Other Links